Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Halozyme Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 552 | 9 | 604 | +61 |
| Shares | 116.3M | 1.14M | 119.3M | +4.12M (+3.6%) |
| Value | $6.05B | $59.6M | $8.75B | +$2.75B (+46.0%) |
9 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (112)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Showing the largest 100 of 112 by value.
Sold out (51)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (9)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 865,568 | $45.0M |
| Congress Wealth Management LLC | 245,177 | $12.8M |
| E Fund Management Co., Ltd. | 19,926 | $1.04M |
| EP Wealth Advisors, LLC | 8,303 | $431.9K |
| Avantax Advisory Services, Inc. | 5,058 | $263.1K |
| First Horizon Advisors, Inc. | 677 | $35.2K |
| Legacy Investment Solutions, LLC | 115 | $5.98K |
| Capital A Wealth Management, LLC | 25 | $924 |
| Parkworth Wealth Management, Inc. | 7 | $364 |